Literature DB >> 10714563

Response to immunization with recall and neoantigens after prolonged administration of an HIV-1 protease inhibitor-containing regimen. ACTG 375 team. AIDS Clinical Trials Group.

H Valdez1, K Y Smith, A Landay, E Connick, D R Kuritzkes, H Kessler, L Fox, J Spritzler, J Roe, M B Lederman, H M Lederman, T G Evans, M Heath-Chiozzi, M M Lederman.   

Abstract

OBJECTIVES: To ascertain if immunization results in the restoration of responses to recall antigens, in the development of responses to presumed neoantigens, and to identify the virologic and immunologic correlates of these responses in persons with HIV-1 infection. DESIGN AND
SETTING: Open-label study carried out at three university-affiliated AIDS Clinical Trials Units in the United States. SUBJECTS AND METHODS: Thirty-one subjects participating in AIDS Clinical Trials Group Protocol 375 who had received zidovudine, lamivudine, and ritonavir for at least 48 weeks. Subjects were immunized with tetanus toxoid (TT) at entry and with inactivated hepatitis A vaccine (hep A) and keyhole limpet hemocyanin (KLH) at entry and 6 weeks. The development of antibody, lymphocyte proliferative assay (LPA), and delayed-type hypersensitivity (DTH) responses after immunization were monitored.
RESULTS: The LPA and DTH responses to TT improved in 57 and 68% of participants, respectively; 73 and 65% developed enhanced LPA and DTH responses to KLH. Forty-eight percent of patients developed a four-fold increase in antibody concentration to tetanus. Seventy-three percent of patients without detectable hepatitis A antibodies at baseline developed antibodies after immunization. Eighty-three percent of patients experienced at least a four-fold rise in KLH antibody concentration. Immune activation and viral load predicted poor recall responses and the number of memory CD4+ T-cells predicted good responses to recall antigens. Naïve CD4+ T-cell numbers, decrease in viral load, increases in CD4+ and CD28+ cells, and decreases in immune activation were associated with responses to presumed neoantigens.
CONCLUSIONS: Most HIV-infected patients treated with potent combination antiretrovirals develop responses to recall and presumed neoantigens after immunization. Functional immune restoration in response to immunization is related to control of viral replication, decreased immune activation as well as to both quantitative and qualitative restoration of circulating T- lymphocyte subpopulations.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10714563     DOI: 10.1097/00002030-200001070-00002

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  34 in total

1.  Immune Reconstitution Strategies in HIV.

Authors:  Matthew R. Leibowitz; Ronald T. Mitsuyasu
Journal:  Curr Infect Dis Rep       Date:  2001-06       Impact factor: 3.725

2.  Dissociation of CD154 and cytokine expression patterns in CD38+ CD4+ memory T cells in chronic HIV-1 infection.

Authors:  Enrique Espinosa; Christopher E Ormsby; Gustavo Reyes-Terán; Robert Asaad; Scott F Sieg; Michael M Lederman
Journal:  J Acquir Immune Defic Syndr       Date:  2010-12       Impact factor: 3.731

Review 3.  A challenge for the future: aging and HIV infection.

Authors:  Tammy M Rickabaugh; Beth D Jamieson
Journal:  Immunol Res       Date:  2010-12       Impact factor: 2.829

4.  Th1/Th2 cytokine profile in patients coinfected with HIV and Leishmania in Brazil.

Authors:  Maria Zilma Andrade Rodrigues; Maria Fernanda Rios Grassi; Sanjay Mehta; Xing-Quan Zhang; Luana Leandro Gois; Robert T Schooley; Roberto Badaro
Journal:  Clin Vaccine Immunol       Date:  2011-08-10

5.  Human immunodeficiency virus type 1 Vpr impairs dendritic cell maturation and T-cell activation: implications for viral immune escape.

Authors:  Biswanath Majumder; Michelle L Janket; Elizabeth A Schafer; Keri Schaubert; Xiao-Li Huang; June Kan-Mitchell; Charles R Rinaldo; Velpandi Ayyavoo
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

6.  Concordance of CCR5 genotypes that influence cell-mediated immunity and HIV-1 disease progression rates.

Authors:  Gabriel Catano; Zoya A Chykarenko; Andrea Mangano; J-M Anaya; Weijing He; Alison Smith; Rosa Bologna; Luisa Sen; Robert A Clark; Andrew Lloyd; Ludmila Shostakovich-Koretskaya; Sunil K Ahuja
Journal:  J Infect Dis       Date:  2011-01-15       Impact factor: 5.226

7.  Clinical implications of discordant viral and immune outcomes following protease inhibitor containing antiretroviral therapy for HIV-infected children.

Authors:  Carina A Rodriguez; Sarah Koch; Maureen Goodenow; John W Sleasman
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

8.  In vitro naïve T cell proliferation failure predicts poor post-immunization responses to neoantigen, but not recall antigens, in HIV-infection.

Authors:  Benigno Rodriguez; Hernan Valdez; Christoph G Lange; Robert Asaad; Kathy Medvik; Scott F Sieg
Journal:  Clin Immunol       Date:  2010-05-15       Impact factor: 3.969

9.  Impaired T-cell responses to sphingosine-1-phosphate in HIV-1 infected lymph nodes.

Authors:  Joseph C Mudd; Patrick Murphy; Maura Manion; Robert Debernardo; Jeffrey Hardacre; John Ammori; Gareth A Hardy; Clifford V Harding; Ganapati H Mahabaleshwar; Mukesh K Jain; Jeffrey M Jacobson; Ari D Brooks; Sharon Lewis; Timothy W Schacker; Jodi Anderson; Elias K Haddad; Rafael A Cubas; Benigno Rodriguez; Scott F Sieg; Michael M Lederman
Journal:  Blood       Date:  2013-02-19       Impact factor: 22.113

10.  Toward identifying the effects of the specific components of Mindfulness-Based Stress Reduction on biologic and emotional outcomes among older adults.

Authors:  Autumn M Gallegos; Michael Hoerger; Nancy L Talbot; Michael S Krasner; Jennifer M Knight; Jan A Moynihan; Paul R Duberstein
Journal:  J Altern Complement Med       Date:  2013-02-05       Impact factor: 2.579

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.